Literature DB >> 32214520

Efficacy of Low-Dose Aripiprazole for Treatment of Psychotic Symptoms in a Patient with 22q11.2 Deletion Syndrome.

Konstantinos Kontoangelos1, Eleni Lazaratou1, Marina Economou1, Konstantina G Yiannopoulou1, Charalambos C Papageorgiou1.   

Abstract

Objectives: The 22q11.2 deletion syndrome is one of the most prevalent genetic disorders and children suffering from this syndrome have been found to have a substantially greater risk for the development of schizophrenia and bipolar disorder. Psychiatric medications such as antipsychotics are commonly used in individuals with 22q11.2DS. Experimental Design: This is a case of 13 years male young man suffering from 22q11.2 deletion syndrome. Since adolescence, he presented with behavioural disorders, aggression, verbal abuse, sleep disorders. Principal Observations: The psychiatric examination confirmed the delusional idea, which was repeated in an obsessive way. There were also auditory hallucinations along with reference ideas. Aripiprazole was administered in 8 mg daily which gave more spectacular results and was better tolerated. Conclusions: In the present situation delusional ideas are no longer mentioned, but a cognitive deduction is found. Aripiprazole can be an effective pharmacological solution for the psychotic symptoms in patients suffering from 22q11DS.
Copyright © 1964–2020 by MedWorks Media Inc, Los Angeles, CA All rights reserved. Printed in the United States.

Entities:  

Keywords:  22q11 deletion syndrome; aripiprazole; psychopharmacology; psychosis; velocardiofacial syndrome

Mesh:

Substances:

Year:  2020        PMID: 32214520      PMCID: PMC7093724     

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  15 in total

1.  Treatment of schizophreniform disorder by aripiprazole in a female adolescent with 22q11.2 deletion syndrome.

Authors:  Ching-En Lin; Kuei-Shwai Hwang; Pei-Hing Hsieh; Chia-Hsing Chi; Nian-Sheng Tzeng
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2010-05-20       Impact factor: 5.067

Review 2.  The 22q11.2 deletion syndrome as a window into complex neuropsychiatric disorders over the lifespan.

Authors:  Rachel K Jonas; Caroline A Montojo; Carrie E Bearden
Journal:  Biol Psychiatry       Date:  2013-08-28       Impact factor: 13.382

Review 3.  Aripiprazole for Tourette's syndrome: a systematic review and meta-analysis.

Authors:  Wei Zheng; Xian-Bin Li; Ying-Qiang Xiang; Bao-Liang Zhong; Helen F K Chiu; Gabor S Ungvari; Chee H Ng; Grace K I Lok; Yu-Tao Xiang
Journal:  Hum Psychopharmacol       Date:  2015-08-26       Impact factor: 1.672

4.  The neuropsychological phenotype of velocardiofacial syndrome (VCFS): relationship to psychopathology.

Authors:  Renée Lajiness-O'Neill; Isabelle Beaulieu; Alexander Asamoah; Jeffrey B Titus; Erawati Bawle; Saadia Ahmad; John W Kirk; Rebecca Pollack
Journal:  Arch Clin Neuropsychol       Date:  2005-11-22       Impact factor: 2.813

5.  High rates of schizophrenia in adults with velo-cardio-facial syndrome.

Authors:  K C Murphy; L A Jones; M J Owen
Journal:  Arch Gen Psychiatry       Date:  1999-10

6.  The neurocognitive phenotype of the 22q11.2 deletion syndrome: selective deficit in visual-spatial memory.

Authors:  C E Bearden; M F Woodin; P P Wang; E Moss; D McDonald-McGinn; E Zackai; B Emannuel; T D Cannon
Journal:  J Clin Exp Neuropsychol       Date:  2001-08       Impact factor: 2.475

7.  Parental origin of the deletion 22q11.2 and brain development in velocardiofacial syndrome: a preliminary study.

Authors:  S Eliez; S E Antonarakis; M A Morris; S P Dahoun; A L Reiss
Journal:  Arch Gen Psychiatry       Date:  2001-01

8.  The schizophrenia phenotype in 22q11 deletion syndrome.

Authors:  Anne S Bassett; Eva W C Chow; Philip AbdelMalik; Mirona Gheorghiu; Janice Husted; Rosanna Weksberg
Journal:  Am J Psychiatry       Date:  2003-09       Impact factor: 18.112

9.  Psychotic symptoms in children and adolescents with 22q11.2 deletion syndrome: Neuropsychological and behavioral implications.

Authors:  Martin Debbané; Bronwyn Glaser; Melissa K David; Carl Feinstein; Stephan Eliez
Journal:  Schizophr Res       Date:  2006-03-20       Impact factor: 4.939

Review 10.  Aripiprazole: from pharmacological profile to clinical use.

Authors:  Guido Di Sciascio; Marco Andrea Riva
Journal:  Neuropsychiatr Dis Treat       Date:  2015-10-13       Impact factor: 2.570

View more
  1 in total

1.  Aripiprazole treatment for temper outbursts in Prader-Willi syndrome.

Authors:  Helge Frieling; Christian K Eberlein; Maximilian Deest; Jelte Wieting; Maximilian Michael Jakob; Stephanie Deest-Gaubatz; Adrian Groh; Johanna Seifert; Sermin Toto; Stefan Bleich
Journal:  Orphanet J Rare Dis       Date:  2022-08-26       Impact factor: 4.303

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.